These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17711715)

  • 1. [Safety and efficacy comparison of myocardial contrast enhancement-guided and angio-pressure-guided transcoronary ablation of septal hypertrophy for patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Wu XS; Jia CQ; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jun; 35(6):540-3. PubMed ID: 17711715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transcoronary ablation of septal hypertrophy versus dual-chamber cardiac pacing for the treatment of aged patients with hypertrophic obstructive cardiomyopathy].
    Gao YC; Li Y; Han ZH; Zhang XL; Zhao H; Jiang TY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Apr; 35(4):333-6. PubMed ID: 17711659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion.
    Kuhn H; Gietzen FH; Schäfers M; Freick M; Gockel B; Strunk-Müller C; Jachmann E; Schober O
    Eur Heart J; 1999 Dec; 20(24):1808-17. PubMed ID: 10581139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy.
    Kuhn H; Gietzen FH; Leuner C; Schäfers M; Schober O; Strunk-Müller C; Obergassel L; Freick M; Gockel B; Lieder F; Raute-Kreinsen U
    Z Kardiol; 2000; 89 Suppl 4():IV41-54. PubMed ID: 10810776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial perfusion and metabolism after transcoronary ablation of septum hypertrophy (TASH) in hypertrophic obstructive cardiomyopathy.
    Lerch H; Schäfers M; Gietzen F; Schäfers K; Kuwert T; Kuhn H; Schober O
    Nuklearmedizin; 1997 Sep; 36(6):218-22. PubMed ID: 9380540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy.
    Gietzen FH; Leuner CJ; Raute-Kreinsen U; Dellmann A; Hegselmann J; Strunk-Mueller C; Kuhn HJ
    Eur Heart J; 1999 Sep; 20(18):1342-54. PubMed ID: 10462469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography.
    Sohns C; Sossalla S; Schmitto JD; Jacobshagen C; Raab BW; Obenauer S; Maier LS
    Clin Res Cardiol; 2010 Jun; 99(6):359-68. PubMed ID: 20503122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Lieder F; Bartelsmeier M; Leuner C; Borchert B; Meyer zu Vilsendorf D; Strunk-Mueller C; Reinhardt J; Feuchtl A; Stellbrink C; Kuhn H
    J Am Coll Cardiol; 2007 Jun; 49(24):2356-63. PubMed ID: 17572252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience].
    Kuhn H
    Z Kardiol; 2000 Jun; 89(6):559-64. PubMed ID: 10929441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term outcomes of transcoronary ablation of septal hypertrophy compared to surgical myectomy in patients with symptomatic hypertrophic obstructive cardiomyopathy.
    Samardhi H; Walters DL; Raffel C; Rateesh S; Harley C; Burstow D; Pohlner P; Aroney C
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):270-7. PubMed ID: 23873660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.
    Gietzen FH; Leuner CJ; Obergassel L; Strunk-Mueller C; Kuhn H
    Heart; 2004 Jun; 90(6):638-44. PubMed ID: 15145866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Kuhn H
    Z Kardiol; 2004 Jun; 93(6):493-9. PubMed ID: 15252744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol septal ablation without myocardial contrast echocardiography for hypertrophic obstructive cardiomyopathy.
    Chamnarnphol N; Wisaratapong T; Cheewatanakornkul S
    J Med Assoc Thai; 2011 Nov; 94(11):1299-303. PubMed ID: 22256468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes.
    Gross CM; Schulz-Menger J; Krämer J; Siegel I; Pilz B; Waigand J; Friedrich MG; Uhlich F; Dietz R
    J Endovasc Ther; 2004 Dec; 11(6):705-11. PubMed ID: 15615561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; He ZX; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Roberts R; Verani MS; Kleiman NS; Spencer WH
    J Am Coll Cardiol; 1998 Jul; 32(1):225-9. PubMed ID: 9669274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial contrast echocardiography guided alcohol septal ablation in hypertrophic obstructive cardiomyopathy with a new echocardiographic contrast agent].
    Pfeiffer B; Rigopoulos A; Seggewiß H
    Dtsch Med Wochenschr; 2012 Oct; 137(41):2093-6. PubMed ID: 23033167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry.
    Kuhn H; Seggewiss H; Gietzen FH; Boekstegers P; Neuhaus L; Seipel L
    Z Kardiol; 2004 Jan; 93(1):23-31. PubMed ID: 14740238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.